Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Palantir Technologies Inc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Palantir Technologies Inc trades at $198.66 (market cap $501.45B). The key difference: Palantir Technologies Inc is far larger — about 96.8× Oruka Therapeutics Inc. Common Stock's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Palantir Technologies Inc for 79 Days on average.
| ORKA | PLTR | |
|---|---|---|
Market Cap | $5.18B | $501.45B |
Volume | 490,798 | 18,438,992 |
Sector | Health | Technology |
52-Week High | $113.08 | $209.05 |
52-Week Low | $26.19 | $107.27 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $4.31B | $492.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Palantir (PLTR) trades at $200.97, down 3.84% on the day but maintains strong bullish technical momentum with consecutive earnings beats. The company demonstrates exceptional fundamental performance with 56.2% revenue growth in 2025, reaching $4.48 billion, and net income margin expanding to 36.3%. Recent partnership with Armada for sovereign AI infrastructure and consistent analyst optimism highlight the stock's growth trajectory despite premium valuation metrics.
Outlook remains positive with accelerating AI adoption driving growth, though elevated P/E of 178.35 presents valuation risk. Wall Street consensus targets $195.86 with 54% buy ratings, while technical indicators show potential resistance near $213-$219 levels. Key risks include growth normalization and competitive pressures in the expanding AI software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
